Mitochondria play a central role in apoptotic signaling pathways. Upon exposure to apoptotic stimuli, mitochondria release cytochrome c to the cytoplasm and activate caspase cascade leading to cell death. However, the events upstream of cytochrome c release are not fully understood. Here, we quantitate mitochondrial aggregation in situ using a novel laser scanning cytometry technique and reveal that mitochondria aggregate during apoptosis in a budding-like shape. The quantitative analysis reveals that mitochondrial aggregation is not inhibited by caspase-3 inhibitor ZEVD. Furthermore, bcl-x L transfection cannot suppress mitochondrial aggregation. However, overexpression of bcl-x L inhibits cytochrome c release from mitochondria. Therefore, mitochondrial aggregation is an event upstream of cytochrome c release during apoptosis. This mitochondrial aggregation was not observed in human leukemia H9 cells where apoptosis occurs in a mitochondria-independent fashion. Our studies imply that changes in the localization of mitochondria participate in the regulation of apoptosis through cytochrome c release.
Introduction
Apoptosis is a mode of cell death that has an important role in normal development and the maintenance of homeostasis (Vaux and Korsmeyer, 1999; Meier et al., 2000) . Various stimuli initiate apoptotic signaling pathways resulting in typical cellular manifestations, such as apoptotic morphological changes and DNA fragmentation (Wyllie, 1980) . Activation of caspases may result in an irreversible commitment of the cell to apoptosis by inducing caspase-mediated substrate cleavage (Tewari et al., 1995; Mashima et al., 1997; Enari et al., 1998; Li et al., 1998; Sakahira et al., 1998; Sahara et al., 1999; Coleman et al., 2001; Sebbagh et al., 2001) . Caspase-3 is a downstream caspase in apoptotic signal transduction (Salvesen and Dixit, 1999; Wolf and Green, 1999) and acts as a key executor of apoptosis by cleaving various cellular substrates, such as inhibitor of caspase-activated deoxyribonuclease (ICAD) Sakahira et al., 1998) , Rho-associated kinase (ROCK I) (Coleman et al., 2001; Sebbagh et al., 2001) , poly(ADP-ribose) polymerase (PARP) (Tewari et al., 1995) , actin (Mashima et al., 1997) , BID , and Acinus (Sahara et al., 1999) .
Mitochondria play a central role in apoptosis (Fearnhead et al., 1998; Green and Reed, 1998; Desagher and Martinou, 2000; Ferreira et al., 2000) by the release of cytochrome c from themselves to the cytoplasm leading to the activation of caspase-cascade system (Liu et al., 1996; Kluck et al., 1997; Yang et al., 1997; Zhivotovsky et al., 1998) . In this study, we showed that mitochondrial aggregation occurred during apoptosis using in situ quantitative technique, and that mitochondrial aggregation was an event upstream of cytochrome c release during apoptosis. Cytochrome c molecules are thought to be released either as a result of direct permeabilization of the outer membrane via a pore, or through the opening of the permeability transition pore, matrix swelling, and rupture of the outer membrane (Reed and Green, 2002; Scorrano et al., 2002) . Although the events upstream of cytochrome c release during apoptosis are not fully understood, these reports suggest that the behavior of mitochondrial molecules such as cytochrome c may be regulated by the behavior of mitochondrial dynamics, and our results are consistent with this concept.
Results

HT-1080 cells undergo caspase-dependent apoptosis after etoposide treatment
Following treatment with etoposide, which is a clinically used anticancer drug, human fibrosarcoma HT-1080 cells detached from the culture dish and floated into the culture medium. Nuclei were observed to be condensed and fragmented (Figure 1c , shown by arrowheads), and cells with a subdiploid DNA content appeared in a timedependent manner (Figure 1e ). These results indicate that etoposide induced apoptotic cell death in the HT-1080 cells. Estimation of caspase activity using a fluorogenic-labeled tetrapeptide acetyl-Asp-Glu-ValAsp-4-methylcoumaryl-7-amide (DEVD-AMC) clearly showed that etoposide treatment induced caspase-3 activation in HT-1080 cells in a time-dependent manner ( Figure 1f) . One of the substrates of caspase-3, PARP, was cleaved to produce a 85-kDa fragment in vivo (Figure 1h , shown by arrowhead). Thus, HT-1080 cells underwent apoptosis with caspase-3 activation following etoposide treatment. In the presence of the competitive inhibitor of caspase-3, carbobenzoxy-Glu-Val-Asp-CH 2 -2, 6-dichlorobenzolate (ZEVD), the etoposideinduced changes in nuclei were suppressed (Figure 1d) . Quantitation of cells with subdiploid DNA content indicated that ZEVD inhibited the etoposide-induced morphological changes in a dose-dependent manner (Figure 1g ). Moreover, etoposide-induced PARP cleavage was inhibited by ZEVD treatment (Figure 1h ). These results indicate that HT-1080 cells underwent apoptosis with caspase-3 activation following treatment with etoposide as has been observed with various cancer cell lines (Haga et al., 1998; Sakamoto et al., 2000) .
Mitochondria aggregate during apoptosis
Mitochondria have been shown to play a central role in anticancer drug-induced apoptosis (Fearnhead et al., 1998; Green and Reed, 1998; Desagher and Martinou, 2000; Ferreira et al., 2000) . Therefore, we focused our studies on mitochondrial dynamics. Under normal growth conditions, mitochondria showed broad cytoplasmic distribution in HT-1080 cells, especially at the periphery of the nucleus (Figure 2a ). After treatment with etoposide for 16 h, a budding-like structure appeared in the cell (Figure 2g , indicated by an arrowhead), and almost all the mitochondria were concentrated in the budding-like structure at one perinuclear locus (Figure 2c , shown by an arrowhead). As the attached cells had normal nuclear structure, they can be interpreted as early apoptotic cells. Typically, cells detach from culture dish following nuclear fragmentation as a part of the apoptotic process. ZEVD treatment did not inhibit etoposide-induced mitochondrial aggregation ( Figure 2d ). Thus, there is no need to activate caspase-3 to produce mitochondrial aggregation. ZEVD alone had no effects on mitochondrial distribution ( Figure 2b ). We observed similar mitochondrial changes after etoposide treatment in other cell lines, such as monkey kidney COS-7 cells and human leukemia U937 cells, and in other apoptotic stimulus SN-38 (a metabolite of the camptothecin derivative, CPT-11)-treated HT-1080 and COS-7 cells (data not shown). In these cases, mitochondrial aggregation occurred during apoptosis and was not inhibited by ZEVD treatment.
To confirm these findings, we compared the rate of mitochondrial aggregation in etoposide plus ZEVDtreated HT-1080 cells with that in nontreated cells using a novel laser scanning cytometry (LSC) technique. We defined max pixel (MP)/area (A) as the index of mitochondrial aggregation. MP is the maximum value of the fluorescence intensity per pixel in an image of mitochondria probed with MitoTracker s Red (MTR), and A is the area of MTR (not of the whole cell). As determined by this quantitation method, we observed that mitochondria were aggregated in cells with higher MP/A (Figure 2l , m). In contrast, MP/A was lower in normal cells (mitochondria are distributed normally; Figure 2j , k) than in cells with aggregated mitochondria. As shown in Figure 2l , we detected a fraction of cells with aggregated mitochondria even without drug treatment. This may be the result of spontaneous apoptosis. The shift to the right in the peak of MP/A following etoposide treatment ( Figure 2i ) indicated an increase in the number of cells with aggregated mitochondria. ZEVD treatment alone did not shift the peak of MP/A (data not shown). These results clearly indicate that mitochondrial aggregation occurs in caspase-3-independent manner in etoposide-treated HT-1080 cells.
Mitochondrial aggregation precedes cytochrome c release during apoptosis
Mitochondria-mediated caspase-3 activation is initiated by the release of cytochrome c from mitochondria to the cytoplasm (Liu et al., 1996; Kluck et al., 1997; Yang et al., 1997; Zhivotovsky et al., 1998) . Therefore, we next examined the distribution of cytochrome c before and after mitochondrial aggregation. Mitochondria were probed with MTR, and cytochrome c was stained with Oregon Green s . In nontreated cells, the merged image of cytochrome c and mitochondria appeared yellow (Figure 3i ), indicating that cytochrome c is located inside the mitochondria. In the etoposide-treated cells, the green image of cytochrome c and the red image of mitochondria were clearly separated (Figure 3k ), suggesting that cytochrome c had been released from mitochondria and that only a few cytochrome c molecules remained in the aggregated mitochondria. As expected, since cytochrome c release is an upstream event relative to caspase-3 activation, ZEVD treatment did not suppress the etoposide-induced cytochrome c release ( Figure 3l ). As shown in Figure 3m , we observed both mitochondrial aggregation and cytochrome c release in etoposide plus ZEVD-treated HT-1080 cells. ZEVD treatment alone did not show any changes in the distribution of either cytochrome c or mitochondria (Figure 3b, f) .
We next examined the response of mitochondria and cytochrome c after etoposide treatment in exogenous Bcl-x L -expressed HT-1080 cells. In Figure 4d , two cells are illustrated with aggregated mitochondria (shown by arrowheads). The lower cell expressed exogenous Bcl-x L protein as indicated by the blue signal, and the other cell (upper cell) did not (Figure 4b ). Although we could detect the release of cytochrome c into the cytoplasm in the Bcl-x L -nonexpressing cell (Figure 4c , upper cell), cytochrome c release was not observed in the Bcl-x Lexpressing cell (Figure 4c , lower cell). It should be noted that mitochondria were aggregated whether cytochrome (Figure 4d ), that is, mitochondrial aggregation could not be suppressed by inhibiting cytochrome c release. We analysed 118 exogenous Bcl-x L -expressing HT-1080 cells in the presence of etoposide. Cytochrome c release was little observed in these cells, but mitochondrial aggregation still occurred in many cells (Figure 4e) . Therefore, the overexpression of Bcl-x L inhibits cytochrome c release without inhibiting mitochondrial aggregation. We confirmed that mitochondrial aggregation was not suppressed by inhibiting cytochrome c release using COS-7 cells transiently transfected with bcl-x L (data not shown), indicating that the phenomenon is not restricted to one particular cell line.
Mitochondrial aggregation occurs in type II cells, but not in type I cells
To further strengthen the conclusion, we examined the changes in mitochondrial distribution using two human leukemia cell lines, H9 and Jurkat. These cell lines are reported to respond differently to an anti-Fas antibody; H9 cell line (called type I cell) undergoes apoptosis in a mitochondria-independent manner after treatment with an anti-Fas antibody, while Jurkat cell line (called type II cell) undergoes apoptosis in a mitochondria-dependent fashion (Scaffidi et al., 1998) . In our experiment, after the 18-h treatment of the cells with 100 ng/ml of anti-Fas antibody, both H9 (type I) and Jurkat (type II) cells underwent apoptosis. We observed that the addition of 100 ng/ml of anti-Fas antibody induced mitochondrial aggregation only in type II Jurkat cells (Figure 5e -h, shown by arrowheads) where apoptosis occurs in a mitochondria-dependent fashion, but not in type I H9 cells (Figure 5a-d) where apoptosis occurs in a mitochondria-independent fashion. These results imply that the mitochondrial aggregation is associated with, and probably an important step for the mitochondriadependent apoptosis.
Discussion
Mitochondria play important roles in apoptotic signal transduction. They regulate the apoptotic signals through Bcl-2 family proteins and cytochrome c release leading to caspase activation. Moreover, mitochondrial dynamics may have an important role in regulating apoptosis. De Vos et al. (1998) have shown that tumor necrosis factor (TNF) induces clustering of mitochondria in murine fibrosarcoma L929 cells and human leukemia U937 cells. Takada et al. (1999) have shown that hepatitis B virus X protein is associated with mitochondria, and induces mitochondrial aggregation leading to cell death with cytochrome c release in human hepatoma and osteosarcoma cell lines. Desagher and Martinou (2000) also showed that mitochondria aggregate around the nucleus in HeLa cells when Bax protein is overexpressed. They reported that condensed mitochondria lost their cytochrome c during this process. These previous reports suggested that mitochondrial aggregation may have a biological meaning during apoptotic signal transduction. To get quantitative information about mitochondrial aggregation, we have analysed HT-1080 cells using laser scanning cytometer (LSC). Unlike flow cytometry, the LSC measures fluorescence and light scatter of cells on slides, so the morphological structure of the samples is preserved. The LSC automatically positions the stage to place the cells of interest in the field of view. LSC is a novel instrument and is more informative for this study than flowcytometry. The method allows generation of information about the cells in situ, and we could quantitatively show that mitochondrial aggregation occurs during apoptosis (Figure 2i ). We also revealed that caspase-3 activation was not involved in the mitochondrial aggregation because a caspase-3 inhibitor ZEVD had no effects on etoposidemediated mitochondrial aggregation (Figure 2d ). Cytochrome c release from mitochondria is an important step for the caspase-3 activation. To assess the role of mitochondrial aggregation during apoptosis, we examined two possibilities for the relation of mitochondrial aggregation (MA; occur ( þ ) or not (À)) and cytochrome c release (CR; þ or À). First, cytochrome c may be released before mitochondrial aggregation. Alternatively, cytochrome c may be released after mitochondrial aggregation. In the former case, we should detect the red ring structure and green fluorescence diffusely around the ring structure (Figure 3m ; À/ þ ). If the cytochrome c is released after mitochondrial aggregation, we should detect yellow aggregated mitochondria (Figure 3m ; þ /À). Counting the number of cells displaying each pattern in the etoposide plus ZEVD-treated cells indicates that there were few À/ þ cells (1.4%; 4/277) when compared to þ /À cells (50.9%; 141/277). These results suggest that mitochondrial aggregation precedes cytochrome c release, and suggests that cytochrome c release is dependent on mitochondrial aggregation. To confirm this hypothesis, we transiently transfected HT-1080 cells with bcl-x L cDNA followed by etoposide treatment. Bcl-x L acts as an apoptosis inhibitory protein by inhibiting cytochrome c release (Jurgensmeier et al., 1998; Narita et al., 1998) . As shown in Figure 4 , Bcl-x L expression suppressed cytochrome c release, but could not inhibit mitochondrial aggregation. By contrast, cytochrome c release was observed in 33.4% (71/ (141 þ 71)) MA þ cells even when cells were treated with the caspase-3 inhibitor ZEVD (Figure 3m ). We also examined whether proapoptotic Bcl-2 family member, Bax, could change the distribution of mitochondria using transient bax-transfected HT-1080 and COS-7 cells. Unfortunately, we could not conclude whether mitochondrial aggregation occur in the Bax-transfected cells because almost all of the transfected cells were shrinking up on the culture dish even in the presence of ZEVD. Our data strongly support the model shown in Figure 6 . First, mitochondria become aggregated after the exposure to apoptotic stimuli. Then cytochrome c is released from the aggregated mitochondria to the cytoplasm resulting in caspase-3 activation. Thus, mitochondrial aggregation is an event upstream of cytochrome c release in the apoptotic process. Recent studies (Guo et al., 2002; Lassus et al., 2002; Paroni et al., 2002; Robertson et al., 2002) suggested that caspase-2 could trigger the release of some mitochondrial proteins including cytochrome c to the cytoplasm. Mitochondrial aggregation might be an event upstream of caspase-2 activation because etoposide-induced mitochondrial aggregation was not inhibited by caspase-2 inhibitor (Z-VDVAD-FMK) (data not shown).
In this study, we succeeded in quantitating mitochondrial aggregation in situ using a novel LSC technique, and showed that mitochondrial aggregation occurred during apoptosis. Experiments using human leukemia cell lines ( Figure 5 ) indicate that the changes in mitochondrial distribution during apoptosis may depend on the contribution of mitochondria to the apoptotic signal transduction system. Scaffidi et al. (1998) have shown that type I cells activate caspase-8 followed by caspase-3 activation independent of mitochondrial activity, and only type II cells seem to depend on mitochondria during apoptosis. Interestingly, mitochondrial aggregation was observed only in type II Jurkat cells ( Figure 5 ) in our experiment. These results imply that the mitochondrial aggregation is associate with, and probably an important step for the mitochondria-dependent apoptosis. Moreover, we discovered that mitochondria aggregated in a buddinglike structure and that mitochondrial aggregation was an event upstream of cytochrome c release during apoptosis. Recently, inhibition of the dynamin-related protein (Drp) 1 that mediates outer mitochondrial membrane fission has been reported to block apoptosis (Frank et al., 2001) . This suggests that mitochondrial dynamics play important roles in apoptosis because mitochondrial morphology and its cellular distribution are regulated by mitochondrial fusion and fission. Further studies of mitochondrial behavior may provide us with novel information to clarify the mechanisms of apoptosis. 
Materials and methods
Cell lines and cell culture
HT-1080 cells were cultured at 371C in a humidified atmosphere of 5% CO 2 and 95% air in Dulbecco's modified Eagle's medium (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum, 2 mm lglutamine, and 100 mg/ml of kanamycin (growth medium). H9 cells (purchased from ATCC; ATCC No. HTB-176) and Jurkat cells were cultured at 371C in a humidified atmosphere of 5% CO 2 and 95% air in RPM11640 medium (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum, 2 mm l-glutamine, and 100 mg/ml of kanamycin (growth medium). All experiments were performed using cells during the logarithmic growth phase.
Induction and detection of apoptosis
HT-1080 cells were treated with 10 mg/ml etoposide in the presence or absence of 100 mm ZEVD. Morphological changes were monitored directly by the phase contrast microscopy and nuclear changes were detected by Hoechst 33342 staining. For apoptosis analysis, 70% ethanol-fixed cells were treated with RNase A, stained with propidium iodide, and analysed by flowcytometry. Cells with subdiploid DNA content were evaluated as apoptotic cells. H9 and Jurkat cells were treated with 100 ng/ml of anti-Fas antibody (clone CH-11) (MBL, Nagoya, Japan) in the presence of 100 mm ZEVD for 18 h.
Measurement of caspase activity
HT-1080 cells were harvested and lysed in buffer containing 25 mm HEPES, 5 mm MgCl 2 , 5 mm EDTA, 5 mm dithiothreitol, 2 mm phenylmethylsulfonyl fluoride, 10 mg/ml pepstatin A, and 10 mg/ml leupeptin, freeze-thawed four times. Insoluble materials were removed by centrifugation (16 000 g, 20 min, 41C), and equal amounts of protein from each cell lysate were then incubated with 50 mm of the fluorogenic substrate DEVD-AMC in IL-1b converting enzyme (ICE)-like enzyme assay buffer (100 mm HEPES, 10 mm sucrose, 0.1 mm CHAPS, and 10 mm dithiothreitol) for 60 min at 301C. The AMC released from the fluoropeptide was measured with excitation at 360 nm and emission at 460 nm using a fluorescence spectrophotometer.
Immunoblot analysis
Cells were solubilized with 2% SDS, 1% 2-mercaptoethanol, 1 mm phenylmethylsulfonyl fluoride, and 50 mm Tris-HCl (pH 6.8). The protein content was determined using a Bio-Rad Protein Assay kit. Whole-cell lysates (50 mg/lane) were subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto a nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). After electroblotting, gels were stained with Coomassie brilliant blue to confirm that equal amounts of the lysates were loaded. Blots were incubated with an anti-PARP p85 Fragment (Promega, WI, USA) and visualized with horseradish peroxidase-conjugated second antibody under chemiluminescence detection (Amersham Japan, Ltd, Tokyo, Japan).
Confocal laser scanning microscopy (CLSM)
HT-1080 cells were cultured in polylysine-coated glass bottom microwell 35-mm dish (MatTek Corporation, MA, USA), and treated with or without 10 mg/ml etoposide and with or without 100 mm ZEVD for 16 h. For the analysis of mitochondria, cells were treated with 0.1 mm MitoTracker s Red CMXRos (Molecular Probes, OR, USA) for 30 min before fixation. Cells were fixed with 4% formaldehyde, permeabilized with methanol, and treated with SYTOX s Green (Molecular Probes, OR, USA) for nuclear staining, or anti-cytochrome c (Pharmingen, CA, USA) for cytochrome c staining. Anticytochrome c-treated cells were visualized with Oregon Green (green fluorescence)-conjugated second antibody (Molecular Probes, OR, USA). Fluorescence was observed by TCS4D confocal laser scanning microscopy (Leica Co., Ltd, Tokyo, Japan) using SCANware software.
Laser scanning cytometry
HT-1080 cells were cultured on a polylysine-coated cover glass (IWAKI, Japan), and were cotreated with 10 mg/ml etoposide and 100 mm ZEVD for 16 h. After staining with MTR and fixation with 4% formaldehyde, fluorescence of MTR was observed by LSC2 laser scanning cytometer (OLYMPUS, Tokyo, Japan) using WinCyte software.
Transient transfection
In all, 2 mg of mouse bcl-x L cDNA in a pFLAG-CMV-2 (Hirotani et al., 1999) were transfected into HT-1080 cells using FuGENEt 6 Transfection Reagent according to the instruction manual (Roche, IN, USA). The cells were treated with 10 mg/ml etoposide for 16 h. Cytochrome c and mitochondria were visualized as above, and exogenous Bcl-x L was visualized with an anti-Octapeptide (ZYMED, CA, USA) and allophycocyanin-conjugated (far-red fluorescence) second antibody (Molecular Probes, OR, USA).
